Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides contract research services in the areas of AIDS, influenza, respiratory syncytial virus, Coronavirus, malaria, hepatitis, cancer, and other infectious diseases, as well as flavivirus infections, including zika and dengue. It also offers small and large animal models. In addition, the company provides cell-based assays, immunoassay, toxicology and cytotoxicity testing, viral load testing, and tailored assay development services; and Biocontainment, imaging services, and animal model development; and IND-enabling services, such as toxicology studies, pharmacokinetic profiling, GLP services, and regulatory documentation services. Bioqual, Inc. was incorporated in 1981 and is based in Rockville, Maryland.
0 transactions — 0 buys and 0 sales reported by Bioqual, Inc. executives.
0 institutional funds report a position on BIOQ in their latest SEC quarterly filing.
1 recent articles on BIOQ.
Beyond raw data, we aggregate and score every smart money signal to give you a unique view.
8-dimension composite score: insiders · hedge funds · politicians · momentum · valuation · health · analysts · earnings.
Detection of clustered purchases or sales by several executives in the same stock.
Berkshire, Pershing Square, Tiger Global, Bridgewater and other reporting funds.
NANC & GOP (Pelosi & Republicans), GURU (top hedge funds), ARK (Cathie Wood). See who enters and exits each week.
Spot marked changes in search interest around the stocks being followed.
Create your watchlist and receive a brief of events affecting your tickers.
This public page only shows a preview. The full analysis of BIOQ on the Kairos Insider dashboard includes:
Free signup · Pro €19/month or €190/year